Neurocrine Adds Epilepsy Assets From Xenon

Xenon will have freedom to focus on later-stage pipeline

Neurocrine plans to advance XEN901 into Phase II in a rare pediatric epilepsy indication while eyeing opportunity in adult focal epilepsy. Xenon increases its runway to develop a pair of mid-stage epilepsy drugs.

Epilepsy awareness concept. Brain and encephalography in epilepsy patient during seizure attack, 3D illustration in purple color
Neurocrine thinks XEN901 offers potential in multiple epilepsy indications

Neurocrine Biosciences Inc. is continuing to bring in assets through a new partnership with Xenon Pharmaceuticals Inc. that adds epilepsy candidates to its pipeline and funds an R&D collaboration with the smaller firm, which enables Xenon to focus more on a pair of Phase II epilepsy candidates it wants to take to market on its own.

Neurocrine announced 2 December that it will pay $50m up front – divided between cash and equity – to obtain...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Atai Gives Up On Recognify’s Schizophrenia Drug After Phase IIb Miss

 
• By 

Set to merge with Beckley Psytech, Atai will focus on psychedelic candidates for treatment-resistant depression while Recognify will analyze Phase IIb data for possible next steps.

Bayer’s Elinzanetant Is Latest Drug Hit By FDA Review Delays

 
• By 

Comes Days After PDUFA Pushback For GSK's Blenrep.

Dr Reddy’s On Semaglutide Prospects, Capacity And There’s An IP Hearing To Watch

 

Dr Reddy’s CEO discusses the growth opportunity for semaglutide, including production capacity and ‘crazy’ demand indications, and a potential 20-plus product GLP-1 portfolio. All eyes are also on an upcoming hearing in India pertaining to Novo Nordisk’s semaglutide patent in the country.

Bristol Appoints AstraZeneca’s Massacesi As Next CMO

 

Chief Medical Officer Samit Hirawat will step down to pursue new career opportunities, the company said.

More from Business

Private Equity Targets Bavarian Nordic But Major Investor Balks

 
• By 

After “intense negotiations”, Bavarian Nordic’s board plans to recommend a DKK19bn ($2.98bn) offer by private equity firms Nordic Capital and Permira to take the company private.

Dr Reddy’s On Semaglutide Prospects, Capacity And There’s An IP Hearing To Watch

 

Dr Reddy’s CEO discusses the growth opportunity for semaglutide, including production capacity and ‘crazy’ demand indications, and a potential 20-plus product GLP-1 portfolio. All eyes are also on an upcoming hearing in India pertaining to Novo Nordisk’s semaglutide patent in the country.

GSK Gains Hengrui’s PDE3/4 Inhibitor, Options For 11 Early Assets In Potential $12bn Deal

 

Deal Snapshot: The addition of Hengrui's HRS-9821, a China-originated fast-follower of Verona’s Ohtuvayre in chronic obstructive pulmonary disease, should enable GSK’s COPD therapy portfolio to stack up well against increasing competitors in the indication, including biologics and small molecules.